IRIDEX (IRIX) Projected to Announce Earnings on Tuesday

Posted by on Aug 11th, 2026

IRIDEX (NASDAQ:IRIX – Get Free Report) is anticipated to post its Q2 2026 results after the market closes on Tuesday, August 18th. Analysts expect the company to post earnings of ($0.01) per share and revenue of $13.5870 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, August 18, 2026 at 5:00 PM ET.

IRIDEX (NASDAQ:IRIX – Get Free Report) last issued its earnings results on Tuesday, May 19th. The medical equipment provider reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.04. The company had revenue of $11.80 million during the quarter, compared to analyst estimates of $11.91 million.

IRIDEX Trading Up 1.4%

NASDAQ:IRIX opened at $0.84 on Tuesday. The firm has a market capitalization of $14.66 million, a PE ratio of -4.43 and a beta of 0.66. The stock has a 50 day moving average of $1.04 and a 200-day moving average of $1.16. IRIDEX has a 52 week low of $0.80 and a 52 week high of $1.65.

Institutional Trading of IRIDEX

Several large investors have recently added to or reduced their stakes in the business. Jane Street Group LLC increased its holdings in shares of IRIDEX by 93.9% during the fourth quarter. Jane Street Group LLC now owns 31,758 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 15,377 shares during the period. Susquehanna International Group LLP lifted its holdings in IRIDEX by 46.2% in the third quarter. Susquehanna International Group LLP now owns 56,470 shares of the medical equipment provider’s stock worth $65,000 after purchasing an additional 17,834 shares during the period. Apexium Financial LP grew its position in IRIDEX by 53.0% in the 3rd quarter. Apexium Financial LP now owns 100,529 shares of the medical equipment provider’s stock valued at $116,000 after buying an additional 34,834 shares in the last quarter. Finally, Citadel Advisors LLC grew its position in IRIDEX by 62.7% in the 3rd quarter. Citadel Advisors LLC now owns 109,473 shares of the medical equipment provider’s stock valued at $126,000 after buying an additional 42,202 shares in the last quarter. 20.10% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Weiss Ratings raised IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, IRIDEX has an average rating of “Hold” and a consensus target price of $3.00.

Check Out Our Latest Research Report on IRIX

IRIDEX Company Profile

(Get Free Report)

IRIDEX Corporation (NASDAQ: IRIX) is a medical technology company specializing in the development, manufacturing and commercialization of innovative ophthalmic laser and imaging systems. The company’s offerings focus on energy-based therapies designed to treat retinal vascular disorders, glaucoma and other ocular conditions. IRIDEX’s portfolio includes laser photocoagulation platforms, micro-pulse laser technology, and related consumable devices for use by ophthalmologists and retina specialists.

The company’s flagship products include the Cyclo G6 Glaucoma Laser System, which delivers precise, controlled micro-pulse laser therapy for patients with refractory glaucoma, and the IQ 532 Retina Laser System, designed to support minimally invasive laser treatments for diabetic retinopathy and age-related macular degeneration.

Featured Stories

Earnings History for IRIDEX (NASDAQ:IRIX)

Receive News & Ratings for IRIDEX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX and related companies with MarketBeat.com's FREE daily email newsletter.